Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s weight loss opportunity as compelling following the stock’s recent selloff.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Giftify reports 916% w/w increase in pharmacy retailer gift cards sold
- Positive Outlook for Novo Nordisk: Strong Data, Expertise, and Next-Gen Developments Drive Buy Rating
- Roche hires Novo Nordisk executive amid obesity drug push, Bloomberg reports
- Novo Nordisk (NVO) Sinks after Weight-Loss Drug Trial Misses Expectations
- Novo Nordisk under pressure as obesity drug disappoints in diabetes trial